Aska Report

Overview

The report presents ASKA Pharmaceutical's FY2018 consolidated performance for the year ended March 31, 2019, including net sales of ¥46,706 million and 842 consolidated employees. It highlights the company's specialty-pharma strategy centered on internal medicine, obstetrics and gynecology, and urology, with a particular focus on women's health. It also describes the relocation of the Kawasaki Research Center to Shonan Health Innovation Park and the launch of Relumina.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2018
Period: 1 April 2018 – 31 March 2019
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services